Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Zmax Approved For One-Dose-Only Antibiotic Therapy

This article was originally published in The Pink Sheet Daily

Executive Summary

Extended-release azithromycin is approved for treatment of mild-to-moderate acute bacterial sinusitis and community acquired pneumonia in adults, Pfizer says. The company said it withdrew an application for acute bacterial exacerbations of chronic bronchitis while FDA "re-evaluates" how it reviews antibiotics for the indication.

You may also be interested in...



Pfizer Citizen Petition Calls For Recall Of Zithromax Generics

Company also files patent litigation against generic azithromycin manufacturers Teva and Sandoz.

Pfizer Citizen Petition Calls For Recall Of Zithromax Generics

Company also files patent litigation against generic azithromycin manufacturers Teva and Sandoz.

Pfizer’s Zithromax Gets Generic Competition Following ANDA Approvals

Teva, Sandoz and Pliva receive FDA clearance for azithromycin; Greenstone launches authorized generic.

Topics

UsernamePublicRestriction

Register

PS062374

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel